Rotaviruses (RVs) enter cells through different endocytic pathways. Bovine rotavirus (BRV) UK uses clathrin-mediated endocytosis, while rhesus rotavirus (RRV) employs an endocytic process independent of clathrin and caveolin. Given the differences in the cell internalization pathway used by these viruses, we tested if the intracellular trafficking of BRV UK was the same as that of RRV, which is known to reach maturing endosomes (MEs) to infect the cell. We found that BRV UK also reaches MEs, since its infectivity depends on the function of Rab5, the endosomal sorting complex required for transport (ESCRT), and the formation of endosomal intraluminal vesicles (ILVs). However, unlike RRV, the infectivity of BRV UK was inhibited by knocking down the expression of Rab7, indicating that it has to traffic to late endosomes (LEs) to infect the cell. The requirement for Rab7 was also shared by other RV strains of human and porcine origin. Of interest, most RV strains that reach LEs were also found to depend on the activities of Rab9, the cation-dependent mannose-6-phosphate receptor (CD-M6PR), and cathepsins B, L, and S, suggesting that cellular factors from the trans-Golgi network (TGN) need to be transported by the CD-M6PR to LEs to facilitate RV cell infection. Furthermore, using a collection of UK ؋ RRV reassortant viruses, we found that the dependence of BRV UK on Rab7, Rab9, and CD-M6PR is associated with the spike protein VP4. These findings illustrate the elaborate pathway of RV entry and reveal a new process (Rab9/CD-M6PR/cathepsins) that could be targeted for drug intervention.
R
otaviruses (RVs) are nonenveloped viruses, members of the family Reoviridae, and the leading etiological agents of viral gastroenteritis in infants and young children worldwide (1) . These viruses are composed of a triple-layered protein capsid that surrounds the viral genome. The outermost layer is composed of two proteins: VP7, which forms the smooth surface of the virus, and the spike protein VP4, which functions as the virus attachment protein (2) . VP4 is cleaved by trypsin into two subunits, VP8 and VP5, and this cleavage is required for the virus to enter the cell (3) (4) (5) (6) (7) . It has been proposed that during the entry process VP4 undergoes structural changes that lead to conversion of the mature infectious RV triple-layered particles (TLPs) into transcriptionally active double-layered particles (DLPs) that start transcribing the viral genome once they reach the cytosolic compartment (8) (9) (10) (11) . Nonetheless, a direct functional correlation of the proposed structural changes in VP4 with cellular factors that might trigger these changes has not been shown.
The initial step in a viral infection is the attachment of the virus to specific receptors on the cell surface, an interaction that frequently triggers cellular signaling cascades that facilitate either virus entry or replication (12) . In most instances, virus internalization proceeds through an endocytic pathway that delivers the viral particle to early endosomes (EEs), characterized by the presence of the GTPase Rab5 and the early endosomal antigen 1 (EEA1) (13) (14) (15) . Some viruses then traffic from these EE compartments to late endosomes (LEs), which are enriched in the GTPase Rab7 (16, 17) . Of the various small GTPases present in endosomes, Rab5 and Rab7 are the most critical for the function of EEs and LEs, respectively (18) . Rab5 is involved in the regulation of the fusion of endocytic primary vesicles with EEs and also in homofusions between EEs (19) (20) (21) , while Rab7 participates in LE formation and cargo transport to lysosomes (22) . The switch from Rab5 to Rab7 occurs via formation of hybrid endosomes that carry both Rab GTPases in separate domains (23) . These endosomes, which are also known as maturing endosomes (MEs) (24) , are also characterized by the presence of intraluminal vesicles (ILVs) that are formed by the endosomal sorting complex required for transport (ESCRT) machinery (25) . The maturation process of late endosomes also involves a drop in the luminal pH and calcium concentration, acquisition of lysosomal components, and formation of additional ILVs (26) . Newly synthesized lysosomal acid hydrolases are delivered from the trans-Golgi network (TGN) to endosomes by mannose-6-phosphate receptors (M6PRs), and recycling of M6PRs back to TGN depends on the small GTPase Rab9 (27) . Among the hydrolases transported to endosome/lysosome bodies from the TGN are cysteine cathepsins, proteases that for a long time were mainly considered protein-degrading enzymes within lysosomes and are currently considered signaling molecules in a variety of biological processes that take place in the extracellular space as well as in the cytosol and nucleus (28) . During their vesicular traffic, viruses are exposed to modifications in the endosomal environment (low pH, low calcium concentration, proteolytic activity, etc.) that trigger conformational changes in the viral particle that promote the delivery of the viral genome into the cytoplasm (29) . Viruses that escape the endocytic compartments from EEs have been defined as early-penetrating (E-P) viruses, while those that reach LEs have been defined as late-penetrating (L-P) viruses (17) .
Several molecules have been identified as cellular receptors and/or coreceptors for RVs, including, sialic acid, integrins, and HSC70 (30) , and more recently, the VP4 protein of some virus strains was found to attach to human histo-blood group antigens (31) (32) (33) (34) (35) . After the initial interactions of the virus with cell surface molecules, different RV strains enter the cells through distinct endocytic pathways that are determined by the spike protein VP4 (36, 37) . Rhesus rotavirus (RRV), one of the most characterized RV strains, enters cells by exploiting a clathrin-and caveolin-independent endocytic pathway (38) , and then it traffics through EEs to reach MEs (39, 40) , where the virion presumably uncoats to yield DLPs that escape the endosomal compartment to enter the cytoplasm. In contrast to RRV, several other RV strains, including bovine rotavirus (BRV) UK, are internalized into the cell through a clathrin-dependent mechanism (36, 37) .
Given the different endocytic pathways employed by rotavirus strains RRV and UK to infect the cell, in this work we determined whether the intracellular traffic used by BRV UK is the same as that used by RRV and whether the transit of BRV UK is also defined by the spike protein VP4. The characterization of these two strains, as well as a collection of UK ϫ RRV reassortant viruses, allowed us to show that BRV UK and RRV differ not only in the endocytic mechanism employed for cell internalization but also in the intracellular traffic of the incoming virus particle. Both RV strains require the formation of ILVs. However, while RRV only needs to reach MEs for cell infection and as such can be considered an E-P virus, BRV UK reaches the LE compartment, behaving as an L-P virus. The differential traffic of these viruses was found to be associated with the spike protein VP4. Importantly, we also found that, in contrast to RRV, the cell entry of BRV UK as well as that of other RV strains of human and porcine origin depends on the GTPase Rab9, the cation-dependent mannose-6-phosphate receptor (CD-M6PR), and the activities of cysteine cathepsins B, L, and S.
MATERIALS AND METHODS

Cells and viruses.
The rhesus monkey epithelial cell line MA104 and the murine fibroblast L929 cell line (ATCC) were grown in advanced Eagle's minimal essential medium (MEM; Invitrogen) supplemented with 5% and 10% fetal bovine serum (FBS), respectively, at 37°C in a 5% CO 2 atmosphere. The RRV strain (G3P [3] ), BRV UK strain (G6P [5] ), and UK ϫ RRV reassortants used in this work were kindly donated by Y. Hoshino (NIAID, NIH, Bethesda, MD) and have been previously described (37, 41) . RRV variant Nar3 and its revertants, clones 14 and 18 (revertant Nar3-14 [rNar3-14] and revertant Nar3-18 [rNar3-18]), have been described previously (42, 43) . Human RV strains Wa (G1P [8] ) and DS-1 (G2P [4] ) were obtained from H. B. Greenberg (Stanford University, Stanford, CA), and RV WI-61 (G9P [8] ) was obtained from F. H. Clark (Wistar Institute, Philadelphia, PA) through M. K. Estes. Simian RV SA11-4S (clone 3; G3P [2] ) was obtained from M. K. Estes (Baylor College of Medicine, Houston, TX), and porcine strain YM (G11P [7] ) was isolated in our laboratory (44) . All RV strains were propagated in MA104 cells as previously described (45) . RV cell lysates were activated with trypsin (10 g/ml) for 30 min at 37°C. TLPs and DLPs of the RRV and BRV UK strains were purified by CsCl isopycnic gradients as described previously (45) . The mammalian reovirus strain type 3 Dearing (ReoT3D) was a kind donation of T. S. Dermody (Vanderbilt University, Nashville, TN). ReoT3D was propagated in L929 cells, and the viral titer was determined in MA104 cells as previously described (36, 46) . Antibodies, reagents, and plasmids. Monoclonal antibodies were used for detection of cellular proteins. Rab5a, EEA1, and Rab7a antibodies were purchased from Abcam (Cambridge, MA), while Rab9a antibody was from GeneTex, Inc. (Irvine, CA). 4=,6=-Diamidino-2-phenylindole (DAPI) and Alexa 488-and 568-conjugated secondary antibodies were purchased from Molecular Probes (Grand Island, NY). Mouse monoclonal antibody against lysobisphosphatidic acid (LBPA) was purchased from Echelon Biosciences Inc. (Salt Lake City, UT). Rabbit hyperimmune sera to purified RV particles (anti-TLPs), RV nonstructural protein 5 (anti-NSP5), and purified reovirus particles (anti-Reo) were produced in our laboratory. Horseradish peroxidase-conjugated goat antirabbit polyclonal antibody was from PerkinElmer Life Sciences (Waltham, MA). Paraformaldehyde (PFA), bovine serum albumin (BSA), Triton X-100, and cathepsin B inhibitor (CA-074) were purchased from Sigma-Aldrich Co. (St. Louis, MO). Ammonium chloride was from J. T. Baker (Center Valley, PA). Cathepsin L inhibitor (Z-FF-FMK) and dimethyl sulfoxide (DMSO) were purchased from Calbiochem, Merck KGaA (Darmstadt, Germany). Leupeptin was obtained from Roche Diagnostics Corporation (Indianapolis, IN). Plasmids expressing Rab5Q79L, Rab5S534N, Rab7, and Rab7NI25I were kindly provided by J. Gruenberg (University of Geneva, Geneva, Switzerland), and their use has been previously described (47, 48) . The plasmids encoding Cdc42 (cell division control protein 42 homolog), Cdc42N17, and Cdc42V12 proteins fused to green fluorescent protein (GFP) were a gift from F. Sanchez-Madrid (Universidad Autónoma de Madrid, Madrid, Spain) (49) . Plasmids expressing cyan fluorescent protein (CFP)-labeled hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), yellow fluorescent protein (YFP)-labeled tumor susceptibility gene 101 (TSG101) and its dominant negative (DN) variant GFP-TSG101/1-157, as well as plasmids expressing CFP-labeled vacuolar protein sorting 4 homolog A (VPS4A) and the DN CFP-VPS4A-E228Q were kindly provided by P. D. Bieniasz (Rockefeller University, New York, NY), and their use has been previously described (50) . The small interfering RNAs (siRNAs) were purchased from DharmaconThermo Scientific (Pittsburg, PA).
Transfection of plasmids and siRNAs. The indicated plasmids were transfected into MA104 cells as previously described (38, 40) . The plasmid transfection efficiency was about 50%. At 8 h posttransfection (hpt), the transfection mixture was removed and fresh advanced Dulbecco modified Eagle medium-5% FBS was added. At 24 to 48 hpt, the cells were infected with the indicated RV strains. The indicated siRNAs were transfected into MA104 cells by a reverse method, as described previously (36) . As a con-trol condition, an irrelevant siRNA against glucose-regulated protein 94 (GRP94) or luciferase (Luc) was used. At 72 hpt, the cells were washed twice with MEM and subsequently infected with the indicated RV strain. None of the assayed siRNAs was cytotoxic at the concentrations used, as determined by a lactate dehydrogenase (LDH) release assay, using a commercial kit (Sigma-Aldrich Co., St. Louis, MO).
Infectivity assays. Virus infectivity was determined by either immunoperoxidase or immunofluorescence focus-forming assays. For the immunoperoxidase assay, MA104 cells were washed twice with MEM and infected at a multiplicity of infection (MOI) of 0.02 with cell lysates of the indicated RV strains or a cell lysate of reovirus T3D. After 1 h of adsorption, the virus was removed, and the cells were washed twice and incubated with MEM for 14 h in the case of RV assays and for 16 h in reovirus assays. Cell monolayers were subsequently fixed, and infected cells were detected as described previously (36) . The detection of viral antigen was optimal at these times postinfection with the immunochemical staining used. Infection of MA104 cells with lipofected RV DLPs was carried out as previously described (36) . For the immunofluorescence assay, MA104 cells grown on glass coverslips were transfected for transient-expression assays or with siRNAs as described above and infected with the indicated virus at an MOI of 3. After 1 h of adsorption, the inoculum was removed and the cells were washed twice with MEM. Since the immunofluorescence assay is more sensitive for detection of viral antigen than the immunoperoxidase assay, the cells were fixed at 6 h postinfection (hpi) and prepared for immunofluorescence. Infected cells were detected by incubation for 1 h at room temperature using a rabbit hyperimmune serum to NSP5 as the primary antibody, followed by incubation with the corresponding Alexa-labeled secondary antibody for 1 h at room temperature. Coverslips were mounted on glass slides using Fluokeep (Exelisis Diagnostics, Athens, Greece). The slides were analyzed with a fluorescence microscope (Zeiss Axioskop 2 mot plus) coupled to a digital camera (Photometrics Cool Snap HQ) as previously described (40) . In the case of transient-expression assays, the infectivity of the indicated RV was determined by considering only the infected cells that expressed either the wild-type protein or the mutant version of interest. Both immunoperoxidase and immunofluorescent assays gave essentially the same results when the infectivity of the viruses was determined. When DLPs were lipofected into cells, they were used at a concentration that would yield about 80% of infected cells in the immunofluorescence assay and to infect cells at an MOI equivalent to 0.02 in the immunoperoxidase assay.
Binding assays. MA104 cells were transfected with the indicated siRNAs as described above. Confluent cells were then washed twice and incubated with MEM for 30 min at 37°C, and virus binding was assayed as previously described (51) . To evaluate virus binding in cells treated with neuraminidase (NA), the assay was carried out as previously described (37) .
Cell treatments. For LBPA-blocking assays, MA104 cells were preincubated with 50 g/ml of anti-LBPA antibody or with 50 g/ml of an isotype IgG control for 16 h and infected with the indicated RV strains for 1 h at 4°C in the absence of antibody. Cells were washed twice, incubated at 37°C in MEM for 6 h, and processed for immunofluorescence assay as previously described (40) . For the assays with protease inhibitors, MA104 cells were pretreated with 25 M leupeptin (in water) or with 5 M cathepsin B or L inhibitors (in DMSO) for 1 h at 37°C. As controls, the cells were mock treated for assays with leupeptin and cathepsin inhibitors. The indicated virus (used to infect cells at an MOI of 0.02) was then adsorbed for 1 h at 37°C in the presence of the inhibitor. The virus inoculum was then removed and cells were washed with MEM. At 14 or 16 hpi (for RV or reovirus infection, respectively), the cell monolayers were fixed and the infected cells were detected by an immunoperoxidase assay as described above. The indicated protease inhibitors were maintained during the entire infection assay. None of the cell treatments with protease inhibitors at the concentrations used was cytotoxic, as determined by the LDH release assay described above.
Colocalization of rotavirus particles with endocytic markers.
MA104 cells grown on glass coverslips were washed twice with MEM. CsCl-purified BRV UK TLPs or an Nar3 lysate (MOI ϭ 50) was added, and the mixture was incubated for 1 h at 4°C; unbound virus was removed by washing, and the cells were incubated in MEM at 37°C for the indicated periods of time. The cells were then fixed, processed for immunofluorescence assay, and analyzed by fluorescence confocal microscopy as previously described (40) . Primary antibodies (monoclonal antibodies to EEA1, Rab7, or Rab9 or anti-TLP antibodies) and secondary antibodies were incubated as previously described (40) . The expressed ESCRT protein HRS was fused to CFP for its detection. Colocalization of cellular proteins and viral particles was visualized using a Bio-Rad MRC confocal microscope coupled to an Axiophot camera (Zeiss) or a Zeiss LSM 510 meta confocal microscope. Each colocalization assay was performed in duplicate cover glasses, and five randomly selected cells per cover glass and per time point were analyzed with ImageJ (version 1.45S) software using a colocalization plug-in, and quantification of the signal was made with a threshold of 0.03 to 1.3 m 2 (40) . Immunoblot analysis. Cells were lysed in Laemmli sample buffer and denatured by boiling for 5 min. The cell lysate samples were then subjected to SDS-PAGE and transferred to Immobilon NC membranes (Millipore, Merck KGaA, Darmstadt, Germany). The membranes were blocked with Tris-buffered saline (TBS) or phosphate-buffered saline containing 5% nonfat dry milk before they were incubated with the indicated antibodies. The bound antibodies were developed by incubation with a peroxidase-labeled secondary antibody and a Western Lightning system (PerkinElmer Life Sciences, Waltham, MA).
qRT-PCR. The efficiency with which siRNAs knocked down the expression of some genes was determined by quantifying the mRNAs encoding the target protein by quantitative reverse transcription-PCR (qRT-PCR) as previously described (40) . To determine the internalization of viral particles, the genomic RNA negative strand was amplified using forward primers for the VP6 RV gene as described previously (52) . The sequences of the forward and reverse primers used to evaluate the CD-M6PR mRNA were 5=-CTGGTAGCAGATGGCTGTGA-3= and 5=-ACTG AGGAAGAGGCTGGACA-3=, respectively.
Statistical analysis. Statistical significance was evaluated by using a two-tailed paired t test with GraphPad Prism (version 5.0) software (GraphPad Software, Inc.). P values of less than 0.05 were considered significant.
RESULTS
Rotavirus strains UK and RRV reach different endocytic compartments during cell infection. RRV and BRV UK enter cells using different endocytic mechanisms (36, 38) . It is not known, however, if both viruses follow the same vesicular traffic upon cell entry. RRV has been shown to exit the endocytic compartment after reaching a mature form of EEs (40), while BRV UK was shown to colocalize with Rab5a, a marker of EEs, suggesting that this virus might also reach the EE compartment (39) . To define the vesicular traffic of BRV UK, we tested the effect of siRNAs directed to various Rab GTPases involved in different steps of the vesicular traffic. For this, MA104 cells were treated with the indicated siRNAs and then were either infected with BRV UK-TLPs or lipofected with BRV UK DLPs, and the resulting virus infectivity was measured by either immunoperoxidase or immunofluorescence focus-forming assays, as indicated in Materials and Methods and the appropriate figure legends. The level of gene silencing by the siRNAs used was evaluated either by Western blotting or by qRT-PCR; all siRNAs used had a silencing efficiency of 80% or more (data not shown). All siRNAs against the three isoforms of Rab5, the early endosomal antigen (EEA1), and the GTPase Cdc42 decreased BRV UK infectivity (Fig. 1A) . In contrast, in cells trans-fected with transcriptionally active BRV UK DLPs, used to bypass the virus entry step, the same siRNAs did not have a significant effect on virus replication. These results suggest that all three isoforms of Rab5, EEA1, and the GTPase Cdc42 that regulates different types of endocytosis are required for BRV UK cell entry. Thus, as recently reported for RRV (39, 40) , BRV UK also seems to reach EEs after entering the cell via clathrin-dependent endocytosis (36) . However, unlike RRV, whose entry pathway was described to be restricted either to EEs (39) or to an ME compartment (40) , the infectivity of BRV UK determined by immunoperoxidase focus-forming assays was found to decrease when the expression of Rab7a and Rab9a was silenced, suggesting that BRV UK needs to reach LEs to infect the cell (Fig. 1B) . The infectivity of transfected BRV UK DLPs was not affected by these siRNAs, indicating again that their effect is limited to virus entry. In these assays, we also evaluated the participation of CD-M6PR in the infectivity of both RRV and UK RV strains. CD-M6PR is involved in the transport of proteins from the TGN to LEs and contributes to the maturation of this compartment (26) . Interestingly, while the infectivity of RRV was not affected by the siRNA against CD-M6PR, that of BRV UK was decreased by this treatment (Fig. 1B) .
The participation of Cdc42, Rab5, and Rab7 in BRV UK infectivity was confirmed by overexpressing constitutively active (CA) and dominant negative (DN) mutants of these proteins (49) . The expression of Cdc42 N17, a DN variant of Cdc42 (49), decreased the infectivity of BRV UK by more than 60% percent compared to that with expression of the wild-type or CA Cdc42 V12 protein (Fig. 1C) , which did not significantly affect it. Among other endocytosis-independent effects, the Cdc42 V12 mutant has been described to block macropinocytosis events by decreasing filopodia formation; thus, as expected, it did not decrease BRV UK infectivity, which depends on clathrin-mediated endocytosis. Rab5Q79L, the CA mutant of Rab5, stimulates the rate of endocytosis and homotypic fusion of EEs but blocks their conversion to late endosomes, whereas the DN Rab5S32N variant prevents vesicle fusion (47); expression of either mutant generated a clear decrease in BRV UK infectivity (Fig. 1C) . Furthermore, in agreement with the RNA interference (RNAi) assays, the expression of the DN mutant of Rab7, Rab7N125I, defective in guanine nucleotide binding (48) , decreased by more than 60% the infectivity of BRV UK compared with that of its wild-type counterpart, confirming that the function of this protein is necessary for the cell entry of BRV UK. Altogether, the previous data suggest that while RRV requires only EE formation, the cell entry of BRV UK requires trafficking from EEs to LEs. In turn, the inhibition of BRV UK infectivity by Rab9a suggests that the transit of CD-M6PR cargo from the TGN to endosomes is needed for cell entry of this RV strain.
BRV UK dependence on Rab7/Rab9 is associated with the VP4 capsid protein. As shown above, BRV UK requires the activity of the small GTPases Rab7 and Rab9 for its infectivity, while RRV does not. To investigate the RV protein(s) associated with the differential vesicular traffic of RRV and BRV UK, the infectivity of reassortant UK ϫ RRV viruses (Table 1) was evaluated in cells treated with either small interfering RNA against Rab7a (siRab7a) or siRab9a ( Fig. 2A and B) . Of interest, the infectivity of reassortants 9, 19, and 20, which contained the VP4 protein from BRV UK origin, decreased significantly in both Rab7a-and Rab9a-silenced cells, while the infectivity of reassortants 25 and 85, which had the VP4 protein derived from RRV, remained unaffected. These results strongly suggest a correlation between the viral origin of the VP4 protein and the virus dependence on Rab7a/Rab9a to infect cells. This observation is reinforced by the fact that reassortant 19, whose infectivity was sensitive to Rab7a/ Rab9a silencing, is a single-gene reassortant virus that contains the BRV UK VP4 gene in an otherwise RRV genetic background, hpi, cells were fixed and virus infectivity was determined by an immunofluorescence assay, as indicated in Materials and Methods. (B) MA104 cells transfected with the indicated siRNA were infected with RV strains RRV and UK at an MOI of 0.02 or lipofected with BRV UK DLPs. At 14 hpi, the cells were fixed and the virus was detected by an immunoperoxidase assay as described in Materials and Methods. In panels A and B, data are expressed as the percent infectivity of the virus compared to that observed in cells transfected with an irrelevant siRNA (Irre), which represents 100% infectivity. (C) MA104 cells were transfected with plasmids encoding the wild-type (wt; for Rab7a and Cdc42) or mutant versions of GTPases Rab5a (Rab5Q79L and Rab5S32N), Rab7 (Rab7125N), and Cdc42 (Cdc42N17 and Cdc42V12). At 24 hpt, the cells were infected with BRV UK and analyzed by confocal fluorescence microscopy, as described in Materials and Methods. BRV UK infectivity in cells expressing the mutant versions of the indicated GTPases was obtained by normalizing against the infectivity observed in cells expressing the respective wild-type protein version or, in the case the Rab5a mutant, against the infectivity observed in cells transfected with the empty plasmid, which in both cases represents 100% infectivity. The arithmetic means Ϯ standard deviations of three independent experiments performed in duplicate are shown. **, P Ͻ 0.01; ***, P Ͻ 0.001. while reassortant 85, which had the BRV UK VP1 and VP7 genes in an RRV genetic background (including VP4), behaved like the parental strain RRV. A monoreassortant containing the VP4 of RRV on the BRV UK genetic background was not available for testing.
The CD-M6PR dependence of BRV UK infectivity correlates with the presence of the spike protein VP4. Following the same strategy described above for Rab7a and Rab9a, we found that VP4 is also associated with the CD-M6PR-dependent infectivity of BRV strain UK, since those UK ϫ RRV reassortant viruses bearing the VP4 protein of BRV UK were also dependent on the activity of this receptor (Fig. 3A) . Since CD-M6PR has also been reported to be present in the cell plasma membrane (reviewed in reference 53), it was possible that silencing of its expression could prevent the attachment of BRV UK to the cell surface. To exclude this possibility, we carried out virus binding assays in CD-M6PR-knockdown cells (Fig. 3B) . The binding of RRV to cells treated with an siRNA against CD-M6PR (siCD-M6PR) was not significantly affected compared to that in control cells transfected with an irrelevant siRNA, while it was severely decreased when the CD-M6PR-knockdown cells were treated with neuraminidase (NA), which removes the sialic acid required for cell attachment of RRV (54) . In contrast, the binding of the UK virus was not affected in CD-M6PR-knockdown cells treated or not with NA (Fig. 3B) , as expected, since BRV UK infection is insensitive to NA treatment (55) , suggesting that CD-MP6R is not relevant for the cell attachment of either BRV UK or RRV. Furthermore, the possibility that interfering with the function of CD-M6PR could prevent the transport or recycling of a BRV UK receptor to the plasma membrane was ruled out by showing that BRV UK internalization, as measured by qRT-PCR of the incoming RNA genomic negative strand, was not reduced under these conditions compared to that in control cells transfected with an irrelevant siRNA (Fig. 3C) , suggesting that knocking down the expression of CD-M6PR does not affect the cell internalization process of this virus. The level of the negative strand observed at 0 min was higher than that observed at 60 min, since under the former condition the genomes of all viruses adsorbed to the cell surface were detected, while at 60 min, the adsorbed virus that had not been internalized was removed by washing with EGTA (see Materials and Methods and the legend to Fig. 3 ). All these data strongly suggest that the dependence of BRV UK on CD-M6PR is associated with the virus spike protein VP4 and that the virus requires CD-M6PR during cell entry after the internalization step.
A single amino acid change in VP4 is associated with the late penetration phenotype of rotavirus. We previously reported that a single amino acid change (Lys to Arg at amino acid 187) in the VP4 protein of Nar3, an NA-resistant mutant of RRV, is responsible for the neuraminidase resistance phenotype, since reversion of arginine 187 to lysine again conferred to the revertant Nar3 virus its neuraminidase sensitivity to virus infection (43) . This amino acid change was also found to be associated with the endocytic pathway, followed by RRV infection of cells. Nar3 as well as UK viruses enter cells by clathrin-mediated endocytosis, while RRV and Nar3 revertant viruses use a poorly defined endocytic pathway that is clathrin and caveolin independent (37) . Since the late penetration phenotype of BRV UK seems to be associated with its VP4 protein, we tested whether the Nar3 mutant also behaved as a late-penetrating (L-P) virus. For this, the roles of GTPases Rab7a and Rab9a and of CD-M6PR on the infectivity of Nar3 were evaluated. We found that the infectivity of Nar3 decreased by 50 to 60% when the cells were previously transfected with siRNA to Rab7a or Rab9a, while the infectivity of revertant viruses rNar3-14 and rNar3-18, as well as that of wt RRV, remained unaffected by this treatment (Fig. 4A) . Overexpression of DN and CA mutants of Rab5a and Rab7a confirmed the functional importance of these GTPases on the entry process of the NA-resistant RRV variant Nar3 (Fig. 4B) . In contrast, it was surprising to find that the infectivity of Nar3 was not affected by knocking down the expression of CD-M6PR, and as such, it behaved differently from BRV UK Table 1 for reassortant compositions). The arithmetic means Ϯ standard deviations of three independent experiments performed in duplicate are shown. ***, P Ͻ 0.001. (Fig. 4C) . Altogether, these results indicate that even though Nar3 reaches late endosomal compartments during the cell entry process, as BRV UK does, it does not require the expression of CD-M6PR, a factor required for BRV UK infection. . After this time, the unbound virus was removed by twice washing the cells with MEM, and the cells were either lysed (time zero min) or shifted to 37°C. After 1 h incubation, the viral particles still present at the cell surface were removed by washing with 3mM EGTA, and the cells were then lysed (time 60 min) as described previously (40) . The total RNA was purified for qRT-PCR as described in Materials and Methods. Data on the amount of the VP6 gene negative strand detected were normalized to the amount of GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA in cells transfected with an irrelevant siRNA. Data represent the arithmetic means Ϯ standard deviations of three independent experiments.
FIG 4
A single-residue change in VP4 associates with the late-penetrating phenotype of RV. (A) MA104 cells transfected with an siRNA against either Rab7a (siRab7a) or Rab9a (siRab9a) were infected with Nar3 or its revertant viruses (rNar3-14 and rNar3-18) at an MOI of 0.02. At 14 hpi, the cells were fixed and immunostained as described in Materials and Methods. (B) MA104 cells were transfected with plasmids encoding the wild-type form of Rab7 and the mutant versions of GTPases Rab5a (Rab5Q79L and Rab5S32N) and Rab7a (Rab7125N) and incubated for 24 h. The cells were then infected with Nar3 at an MOI of 5, and at 6 hpi they were fixed, processed for immunofluorescence assay, and analyzed by confocal fluorescence microscopy as described in Materials and Methods. The infectivity of Nar3 in cells expressing the mutant versions of the indicated GTPases was obtained by normalizing against the infectivity observed in cells expressing the respective wild-type version or, in the case of the Rab5 mutant, against the infectivity observed in cells transfected with the empty vector, which in both cases represents 100% infectivity. (C) MA104 cells transfected with an siRNA against CD-M6PR were infected with the indicated viruses at an MOI of 0.02. At 14 hpi, the cells were fixed and immunostained as described in Materials and Methods. In panels A and C, data are expressed as the percent infectivity of each virus compared to the level of infectivity of cells transfected with an irrelevant siRNA, which represents 100% infectivity. For all the panels, the arithmetic means Ϯ standard deviations of at least three independent experiments performed in duplicate are shown. **, P Ͻ 0.01; ***, P Ͻ 0.001.
ESCRT and the formation of ILVs are important for cell entry of late-penetrating rotaviruses. The involvement of ESCRT and ILV formation in the cell entry of RV strains RRV, Wa, and DS-1 was recently reported (40) . Thus, in this work we also evaluated if this complex is required by the L-P RV strains UK and Nar3. MA104 cells were treated with siRNAs targeting the proteins HRS, TSG101, and VPS24, members of the ESCRT-0, -I, and -II complexes, respectively, and the ATPase VPS4A, whose function is essential for the scission of ILVs in maturing endosomes to generate multivesicular bodies (MVBs) (24) . The infectivity of RVs UK and Nar3 in MA104 cells in which the ESCRT components were silenced decreased by more than 60% compared with that in cells transfected with an irrelevant siRNA (Fig. 5A) ; these siRNA treatments had no effect on the infectivity of lipofected, transcriptionally active DLPs (shown for BRV UK in Fig. 5A ), suggesting that the ESCRT machinery participates in BRV UK infection at the cell entry level.
To confirm the results obtained with the RNAi approach, we tested the effect of overexpressing DN mutants of the ESCRT proteins TSG101 and VPS4A on Nar3 and BRV UK infectivities. MA104 cells expressing the mutant version of TSG101, TSG101-DN, which lacks the ability to interact with other components of the ESCRT-0 complex (50), showed a 45% decrease in infection with both viruses (Fig. 5B) , while the overexpression of the functionally impaired VPS4A mutant, VPS4A-E228Q (50), decreased the infectivity of the Nar3 and UK viruses by more than 70%, suggesting that the ESCRT formation of ILVs is required for these viruses to enter cells. This conclusion is supported by the fact that an antibody blocking the phospholipid lysobisphosphatidic acid (LBPA), which is crucial for ILV formation, inhibited the infectivity of BRV UK by more than 60% compared to that of cells exposed to a control IgG (Fig. 5C ).
Rotavirus colocalization with intracellular traffic components. To further characterize the entry process of RV strains UK and Nar3, we analyzed by confocal microscopy the colocalization of the incoming virus particles with the ESCRT protein HRS, the endosomal markers EEA1 and Rab7a, as well as the GTPase Rab9a. For this, MA104 cells were incubated with the indicated virus for 1 h at 4°C, washed, and shifted to 37°C for the indicated periods of time (Fig. 6) . The cells were then fixed, incubated with the specific primary and secondary antibodies, and processed for confocal microscopy. Viruses, EEA1, and Rab GTPases were detected by indirect immunofluorescence, while HRS was detected directly in cells that were transfected with a plasmid encoding a fusion of HRS and the cyan fluorescent protein (HRS-CFP). Both viruses were found to colocalize with all the cellular molecules assayed (Fig. 6A and B) . The times required to achieve the maximum signal and percent colocalization are shown in Fig. 6C . While both the UK and Nar3 viruses presented the same progression of colocalization with endosomal markers (HRS-EEA1-Rab7-Rab9), the kinetics appeared to be slightly dissimilar and were more apparent in the initial minutes. According to the maximum time required to achieve RV colocalization with the indicated cellular protein, RV mutant Nar3 reached the endosomal compartments earlier than the BRV UK strain. The colocalization of the UK and Nar3 viruses with the proteins HRS, EEA1, Rab7a, and Rab9a supports the participation of these proteins in virus entry.
Most rotavirus strains behave as L-P viruses. To characterize whether other RV strains behave as L-P viruses, the vesicular traffic of SA11-4S, Wa, WI61, DS-1, and YM, all of which enter cells by clathrin-mediated endocytosis (37), was evaluated. RRV was used as a control virus. The infectivity of these viruses was evaluated in MA104 cells in which the expression of Rab5a, Rab7a, and Rab9a was silenced by RNAi. As expected, the infectivity of all RV strains tested was significantly decreased in cells with knocked down expression of Rab5a (Fig. 7A) . Of interest, the infectivity of RV strains Wa, WI61, DS-1, and YM was also significantly decreased in cells transfected with siRNAs against Rab7a (Fig. 7B) , Rab9a (Fig. 7C) , and CD-M6PR (Fig. 7D) , while the infectivity of the clathrin-dependent simian strain SA11-4S (37) remained unaffected, as observed for the clathrin-independent strain RRV. These data suggest that, with exception of RRV and SA11-4S, all other RV strains need to reach late endosomes and depend on the function of Rab9 and CD-M6PR to infect the cell. These results DN) . At 24 and 48 hpt, respectively, the cells were infected with BRV UK or Nar3 (MOI ϭ 5), and at 6 hpi, the cells were fixed, prepared for immunofluorescence assay, and analyzed by confocal microscopy as described in Materials and Methods. Virus infectivity in cells expressing the mutant versions of the indicated ESCRT proteins was obtained by normalizing against the infectivity observed in cells expressing their respective wild-type protein, which represents 100% infectivity. (C) MA104 cells were mock incubated (no treatment [NT]) or incubated with 50 g/ml of either antibody to LBPA (anti-LBPA) or a control IgG isotype antibody (Control IgG) for 16 h. Cells were then inoculated with BRV UK at an MOI of 5 for 1 h at 4°C in the presence of the respective antibody before they were washed twice and incubated in MEM at 37°C for 6 h. Cells were fixed and processed for immunofluorescence assay as described in Materials and Methods. Data are expressed as the percent infectivity of BRV UK compared to the level of infectivity of cells incubated with a control isotype antibody, which represents 100% infectivity. The arithmetic means Ϯ standard deviations of three independent experiments performed in duplicate are shown. **, P Ͻ 0.01; ***, P Ͻ 0.001. also suggest that there is not a direct correlation between the type of endocytosis used by the virus to enter the cell (clathrin dependent or independent) and the vesicular traffic followed afterwards.
Cathepsins are required for BRV UK cell entry. Since newly synthesized endosomal/lysosomal acid hydrolases are known to be delivered from the TGN to endosomes by M6PRs (53), we evaluated the potential role of cathepsins on the infectivity of BRV UK, which was used as a model strain for L-P RVs. Cathepsins are important components of lysosomes, and they are transported from the TGN to these organelles through LEs; in LEs the proenzyme is proteolytically processed into the active form, which is then delivered to lysosomes (28) . To test the role of cathepsins on BRV UK infection, we used specific inhibitors of the cysteine-acid proteases cathepsin B (CA-074) and cathepsin L (Z-FF-FMK), as well as leupeptin, a broad-spectrum inhibitor of endosomal/lysosomal proteases. We also tested the effects of these inhibitors on the infectivity of RRV, Nar3, and the revertant virus rNar3-14, since these viruses did not seem to depend on the CD-M6PR. As a positive control, we used reovirus type 3 Dearing (ReoT3D), since its infectivity is known to depend on the activity of cathepsins B, L, and S (56, 57) . Leupeptin inhibited the infectivity of BRV UK by 40%, while it did not affect the infectivities of RRV, Nar3, and the revertant virus (Fig. 8A) ; as previously reported, the infectivity of or Nar3 (B) RV TLPs (MOI ϭ 50) for 1 h at 4°C to promote virus attachment to the cell surface. The cells were then promptly shifted to 37°C, fixed at several times, as indicated, and processed for immunofluorescence assay. Virus particles were detected using anti-TLP primary antibodies and secondary antibodies labeled with Alexa 568. HRS was coupled to CFP; EEA1, Rab7, and Rab9 were detected with specific monoclonal antibodies and Alexa 488-conjugated secondary antibodies. Representative images are shown. (C) Times required to achieve the maximum signal and percent colocalization.
a , data represent the maximum time (minutes postattachment) required to achieve RV colocalization with the indicated cellular protein; b , data represent the percent viral colocalization with the indicated cellular markers at the corresponding time points. ReoT3D was decreased by almost 100-fold. When the cathepsinspecific inhibitors were tested, we found that the inhibitor of cathepsin B decreased the infectivity of BRV UK and ReoT3D to about the same level (40%), while the infectivities of RRV, Nar3, and the revertant virus were not affected (Fig. 8B) . The inhibitor of cathepsin L had the same effect on all RV strains as the inhibitor of cathepsin B, but it had a much more pronounced effect on the infectivity of ReoT3D (Fig. 8C) . To confirm these results, we silenced the expression of cathepsins B, L, and S in MA104 cells by RNAi. Silencing the expression of these three cathepsins caused a reduction of BRV UK infectivity of about 40%, while the infectivity of RRV, Nar3, and rNar3-14 remained unaffected (Fig. 8D to  F) . The infectivity of ReoT3D under these conditions was somewhat similar to that of BRV UK, since it was decreased by about 60% with siRNA against cathepsins B and S (Fig. 8D and F ) and about 80% with siRNA against cathepsin L (Fig. 8E) . Altogether, these findings support a role of cathepsins on the infection of cells by BRV UK.
DISCUSSION
Regardless of the nature of the cell surface receptor used and the endocytic pathway employed for cell internalization (39, 40; this work), all RV strains seem to converge in EEs during cell entry, since their infectivities depend on the activities of Rab5 and EEA1 (Fig. 9) . However, after EEs, the various RV strains apparently follow different routes to reach the cytoplasm. RRV and SA11-4S presumably exit the vesicular compartments from ME, as judged by the fact that their infectivities do not seem to depend on Rab7. On the other hand, the infectivity of RV strains UK (bovine), YM (porcine), Wa, WI61, and DS-1 (human), and Nar3, the NA-resistant variant of RRV, depends on the expression of this GTPase, suggesting that these viruses continue a deeper journey into the cell that depends on the ESCRT machinery (shown for BRV UK in this work and for human strains Wa and DS-1 in reference 40) to reach LEs. This late endosomal compartment likely provides the optimal environment for the Rab7-dependent strains to enter the cytosol. In this regard, Rab7-dependent RVs behave as late-penetrating (L-P) viruses (17) , while simian RV strains RRV and SA11-4S can be considered early-penetrating (E-P) viruses (17) . Of interest, all RV strains that reach LEs also require a functional Rab9a GTPase to infect the cell, and all of them, with the exception of Nar3, also require the activities of the CD-M6PR and cathepsins (Fig. 9) .
The maturation process of LE involves a drop in luminal pH, the acquisition of lysosomal components, the exchange of membrane components, movement to the perinuclear area, a shift in choice of fusion partners, the formation of additional ILVs, and changes in morphology (26) . As part of this maturation, proteins traffic between the TGN and endosomes, and vice versa; the list of these proteins is expanding rapidly, as are their functions (reviewed in references 27, 58, and 59). The most characterized examples are the two types of M6PRs (27) . M6PRs deliver newly synthesized lysosomal enzymes from TGN to endosomes and then return to the Golgi complex to bring more cargo. Two M6PRs have been described, the 46-kDa cation-dependent CD-M6PR and the 300-kDa cation-independent M6PR (CI-M6PR). Both types of M6PRs bind lysosomal enzymes, but they can also selectively transport other cargoes, such as insulin-like growth factor II and transforming growth factor ␤1, among others (53) . The fact that the infectivity of L-P RV strains decreases when the expression of CD-M6PR is silenced suggests that to exit LEs, these viruses need a cellular factor transported from the TGN to LEs by the CD-M6PR. One of the main cargoes of M6PR are cathepsins, proteases that mostly work at acidic pH.
Of interest, endolysosomal cysteine cathepsins are also required for reovirus capsid processing and infectivity (56, 57) . The limiting step to begin the disassembly cascade of reovirus, once it has reached the endosomal compartment, is the removal of the 3 protein by cathepsins B and L, which eventually leads to endosomal membrane rupture and delivery of transcriptionally active core particles into the host cell cytoplasm. Cathepsin S, a neutral pH cysteine protease, has also been shown to mediate uncoating of some reovirus strains in a macrophage cell line (60) .
Cysteine cathepsins have also been involved in the entry of other viruses. It has been shown that the endolysosomal processing by cathepsins B and L of the Ebola virus glycoprotein is essential for delivery of viral material into the cytosol (61) . Cleavage of the GP1 subunit of the virus spike glycoprotein by cathepsins reveals a putative binding domain for the endolysosomal cholesterol transporter Niemann-Pick type C1, which promotes virus fusion with the limiting membrane of LEs (62) . Inhibitors of cathepsin L also prevent severe acute respiratory syndrome coronavirus entry; it has been proposed that the viral glycoprotein is cleaved by cathepsin L, what activates the fusion of viral and endosomal membranes (63) . Activation of the Nipah virus fusion protein in MDCK cells also seems to be mediated by cathepsin B within the endosome-recycling compartment, which is a prerequisite for the production of infectious particles and for virus spread via cell-tocell fusion (64) .
In this work, we show that cathepsins B, L, and S are required for BRV UK infection but not for RRV or Nar3. Their precise role in RV entry remains to be determined, but on the basis of the observation of the role of these proteases in other virus systems, it is tempting to speculate that these endosomal proteases process one or the two virus surface proteins to promote the exodus of the DLP into the cytoplasm. As observed in the case of Ebola virus, the possibility cannot be excluded, however, that after the putative cathepsin processing of viral proteins there is an additional cell factor needed for the virus to leave the endosomal compartment (65) . Of interest, the fact that the infectivity of Nar3 was dependent on Rab7 and Rab9 but independent of CD-M6PR suggests either that it does not need TGN cell components for infectivity or that the required component is transported by a different shuttle system (58) . In this regard, it is of interest that the infectivity of Nar3 was not affected either by knockdown of the expression of cathepsins B, L, and S or by treatment with cathepsin inhibitors.
Given that CD-M6PR is required for the productive infectivity of most L-P RVs, the finding that Rab9a is also required is not surprising, since this GTPase resides predominantly in LEs and is required for the transport of M6PRs from endosomes to the TGN (66, 67) . Thus, silencing the expression of Rab9 affects the retrograde transport of the CD-M6PR and, ultimately, the arrival to LEs of hydrolases and other Golgi apparatus components that might be required for RV infection. CD-M6PR has so far not been implicated in the cell entry process of any other virus.
UK ϫ RRV reassortant viruses were previously used to show that the clathrin-dependent or -independent endocytic pathways followed by BRV UK and RRV, respectively, were associated with the spike protein VP4, and it was also shown that a single amino acid change in VP4 dictated the route of entry (37) . Remarkably, in this work we found that the dependence of BRV UK infectivity on Rab7, Rab9a, and CD-M6PR is also associated with VP4, since the presence of BRV UK VP4 correlated with the L-P phenotype of the reassortant. Furthermore, in this work we also showed that a point mutation in VP4 is able to convert RRV from a virus independent of Rab7 and Rab9 into a virus dependent on Rab7 and Rab9, since the RRV mutant virus Nar3, but not its revertant viruses, required the activity of these small GTPases for infectivity.
In addition to proteins transported by CD-M6PR from TGN to LEs, it is likely that factors such as acidic pH or the low luminal calcium concentration of endosomes could be part of the requirement for E-P and L-P RVs to get uncoated and exit the endosomal compartment. In this regard, it has been reported that preventing endosomal acidification with NH 4 Cl and other weak bases does not block the infection of RRV (36, 38, 68, 69) , but it reduces the infectivity of RVs UK and Wa (36) , as well as the infectivity of those UK ϫ RRV reassortants bearing BRV UK VP4 (M. A. Díaz-Salinas et al., unpublished results). These findings support the idea that, in contrast to RRV, the L-P RVs UK and Wa could require the low pH of LEs to initiate viral replication in the cell. Regarding the role of endosomal calcium on RV entry, it is known that the in vitro stability of RV TLPs depends on the presence of calcium. If calcium is removed from the medium by chelation, the outer layer disassembles, yielding DLPs (70) . Thus, it has been proposed that after virus entry by endocytosis, a drop in the luminal calcium concentration in the endocytic vesicle leads to virus uncoating, yielding a DLP that reaches the cytoplasm through a disrupted vesicle membrane (71) . On the other hand, it has been shown that RRV uncoats in vitro at a calcium concentration of 10 nM, while BRV UK does it at 600 nM (70) . Thus, one would expect that if the only trigger for the release of the outer capsid is the calcium concentration, as it decreases with the progressive maturation of the endosome (72), BRV UK would uncoat before RRV does. However, the results presented in this work show that RRV uncoats and likely reaches the cytosolic compartment from MEs, while BRV UK has to reach LEs, where the calcium concentration is even lower, before its exit to the cytoplasm. These observations suggest that RV uncoating in infected cells is an event more complex than that observed in vitro and most likely depends on a combination of factors, such as the interplay between pH and calcium concentration, as well as on cysteine proteases and possibly other uncharacterized protein cellular factors.
For RV strains RRV and UK and likely for most, if not all, RVs, the internalization (37) and the vesicular traffic of the virus during cell infection are associated with the VP4 protein (this work). Although the time and place as well as the specific factors that lead to virus uncoating have not been defined, it has been proposed that for this process to occur, the spike protein VP4 first has to undergo an initial conformational change, triggered by an unknown factor, that in turn promotes the release of the smooth VP7 surface layer in the endosome, converting the TLP into a DLP. This virus disassembly step is then believed to cause a more drastic rearrangement of the VP5 subunit of VP4 to a fold-back conformation that leads to the interaction of its hydrophobic domain with the endosomal membrane and disrupts it (9, 10, 73) . Thus, the observation that RRV reaches MEs to infect the cell, while BRV UK and the other L-P RVs characterized in this work need to reach LEs, probably reflects the difference in the endosome luminal conditions required to induce the VP4 conformational changes of the different RV strains. Likewise, the fact that a single amino acid change in the VP4 protein of RRV changes the virus behavior from E-P to L-P most likely reflects the specific endosomal environment required for uncoating this virus.
Many enveloped viruses belonging to different virus families have been described to reach LEs during infection (17) . However, the vesicular traffic of nonenveloped viruses has been less characterized; mouse polyomavirus, simian virus 40, human papillomavirus, human rhinovirus, canine parvovirus, reovirus, and bluetongue virus have been reported to reach LEs (17, (74) (75) (76) , although none of these viruses has been shown to depend on M6PRs for cell entry.
Despite the advances in the knowledge of the complete cell entry process of RV during cell infection that has taken place in recent years, there are still many questions that remain to be answered, including the possible existence of a so far unknown cell receptor that might play a major role during virus internalization; the role of pH and calcium concentration during cell entry; the place and time of virus uncoating and entry into the cytoplasm; the factors that trigger the conformational changes of VP4; the mechanism of viral permeation and/or disruption of the endosomal membrane; the possible cellular factor(s) of the TGN, other than cathepsins, that might be involved in the cell entry of L-P viruses; and the specific role of cathepsins in RV infection. Most importantly, it remains to be determined if all the events observed in cells of the MA104 cell line, the cell line most commonly used to study RV replication, occur in intestinal enterocytes during a natural infection. Whatever the answers might be, the findings presented in this work show that RVs are versatile, highly evolved entities that take advantage of different cellular processes to their benefit.
